Biotech Sector Considers New Funding Vehicle: FDA Priority Review Voucher

Big Pharma execs say vouchers may be worth $100 million to $200 million. Two small-cap biotechs among those hoping to cash in.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet